Valeant Pharmaceuticals International (VRX) Buys-Out Rights to All Current and Future Income and Milestone Obligations From Former Dow Pharmaceutical Sciences (JOBS) Stockholders for $115M
9/29/2009 9:15:17 AM
More...
|
Dow Pharmaceutical Sciences Becomes Wholly Owned Subsidiary as Acquisition by Valeant Pharmaceuticals International (VRX) is Completed
1/9/2009 11:51:56 AM
More...
|
Valeant Pharmaceuticals International (VRX) Completes Acquisition of Dow Pharmaceutical Sciences
1/2/2009 10:53:04 AM
More...
|
Valeant Pharmaceuticals International (VRX) to Acquire Dow Pharmaceutical Sciences for $285 Million
12/10/2008 6:29:04 AM
More...
|
Dow Pharmaceutical Sciences to Present Scientific Poster at American Association of Pharmaceutical Scientists Evaluating the Affect of Flow Rate, Tissue Thickness and Receptor Phase Type on Drug Penetration When Appied Topically to Human Dermatomed and Dermis Only Skin
10/30/2008 11:08:19 AM
More...
|
Dow Pharmaceutical Sciences Expands Clinical Labeling Capabilities in Petaluma, California
9/4/2008 8:25:29 AM
More...
|
Kaken Pharmaceuticals To License Its Antifungal Compound KP-103 To Dow Pharmaceutical Sciences
5/11/2006 3:18:58 PM
More...
|
DOR BioPharma, Inc. (DOR) And Dow Pharmaceutical Sciences Complete Feasibility Study For Production Of BT-VACC
11/17/2005 11:51:42 AM
More...
|
FDA Receives Dow Pharmaceutical Sciences Approval Of NDA For Galderma's Clobex(R) Spray For Moderate-To-Severe Plaque Psoriasis
11/2/2005 11:00:57 AM
More...
|
Dr. Daniel Bucks, Director Of The Skin Biology And Drug Delivery Laboratory At Dow Pharmaceutical Sciences, Speaks On Skin Permeation Enhancement Techniques At AAPS Convention In Baltimore
10/19/2005 5:12:23 PM
More...
|
|